Show simple item record

Files in this item


Item metadata

dc.contributor.authorInsel, T R
dc.contributor.authorVoon, V
dc.contributor.authorNye, J S
dc.contributor.authorBrown, Verity Joy
dc.contributor.authorAltevogt, B M
dc.contributor.authorBullmore, E T
dc.contributor.authorGoodwin, G M
dc.contributor.authorHoward, R J
dc.contributor.authorKupfer, D J
dc.contributor.authorMalloch, G
dc.contributor.authorMarston, H M
dc.contributor.authorNutt, D J
dc.contributor.authorRobbins, T W
dc.contributor.authorStahl, S M
dc.contributor.authorTricklebank, M D
dc.contributor.authorWilliams, J H
dc.contributor.authorSahakian, B J
dc.identifier.citationInsel , T R , Voon , V , Nye , J S , Brown , V J , Altevogt , B M , Bullmore , E T , Goodwin , G M , Howard , R J , Kupfer , D J , Malloch , G , Marston , H M , Nutt , D J , Robbins , T W , Stahl , S M , Tricklebank , M D , Williams , J H & Sahakian , B J 2013 , ' Innovative solutions to novel drug development in mental health ' , Neuroscience and Biobehavioral Reviews , vol. 37 , no. 10 Part 1 , pp. 2438-2444 .
dc.identifier.otherPURE: 89468127
dc.identifier.otherPURE UUID: bc572ec1-4f34-4f53-8b29-3dd3923ff21d
dc.identifier.otherWOS: 000330490100012
dc.identifier.otherScopus: 84890235819
dc.identifier.otherORCID: /0000-0001-5762-1797/work/63380696
dc.description.abstractThere are many new advances in neuroscience and mental health which should lead to a greater understanding of the neurobiological dysfunction in neuropsychiatric disorders and new developments for early, effective treatments. To do this, a biomarker approach combining genetic, neuroimaging, cognitive and other biological measures is needed. The aim of this article is to highlight novel approaches for pharmacological and non-pharmacological treatment development. This article suggests approaches that can be taken in the future including novel mechanisms with preliminary clinical validation to provide a toolbox for mechanistic studies and also examples of translation and back-translation. The review also emphasizes the need for clinician-scientists to be trained in a novel way in order to equip them with the conceptual and experimental techniques required, and emphasizes the need for private-public partnership and pre-competitive knowledge exchange. This should lead the way for important new holistic treatment developments to improve cognition, functional outcome and well-being of people with neuropsychiatric disorders.
dc.relation.ispartofNeuroscience and Biobehavioral Reviewsen
dc.rights© 2013 Elsevier Ltd. All rights reserved. Published as open access.en
dc.subjectPharmacological tool boxen
dc.subjectCognitive and psychosocial treatmentsen
dc.subjectNovel drug developmenten
dc.subjectNeurobiological mechanismsen
dc.subjectNeuropsychiatric disordersen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleInnovative solutions to novel drug development in mental healthen
dc.typeJournal articleen
dc.contributor.sponsorThe Royal Societyen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Psychology and Neuroscienceen
dc.contributor.institutionUniversity of St Andrews. Office of the Principalen
dc.contributor.institutionUniversity of St Andrews. Institute of Behavioural and Neural Sciencesen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record